Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
Angiogenesis Inhibitors
/ adverse effects
Animals
Bisphosphonate-Associated Osteonecrosis of the Jaw
/ etiology
Bone Density Conservation Agents
/ adverse effects
Bone and Bones
/ diagnostic imaging
Denosumab
/ adverse effects
Diphosphonates
/ adverse effects
Disease Models, Animal
Female
Fluvastatin
/ pharmacology
Osteonecrosis
/ etiology
Rats
Rats, Wistar
Tooth Extraction
/ adverse effects
Zoledronic Acid
/ adverse effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 03 2020
27 03 2020
Historique:
received:
03
11
2019
accepted:
01
03
2020
entrez:
30
3
2020
pubmed:
30
3
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Medication-related osteonecrosis of the jaw (MRONJ) occurs in patients undergoing oral surgery while medicated with bisphosphonate, denosumab or anti-angiogenic agents. We employed a MRONJ-like rat model to investigate whether injecting fluvastatin at extraction sites prevents MRONJ-like lesion. A MRONJ-like model was created by treating rats with zoledronate and dexamethasone, extracting teeth, and immediately injecting fluvastatin at the extraction site. The experimental group comprised three subgroups treated with low (0.1 mg/kg; FS-L), medium (1.0 mg/kg; FS-M) and high concentrations (10 mg/kg; FS-H) of fluvastatin. Necrotic bone exposure was significantly lower in the FS-M (p = 0.028) and FS-H (p = 0.041) groups than in the MRONJ group. The distance between the edges of the epithelial surfaces was significantly shorter in the FS-M (p = 0.042) and FS-H (p = 0.041) groups. The area of necrotic bone and the necrotic bone ratio were significantly smaller in the FS-H group (p = 0.041 and p = 0.042 respectively). Bone volume fraction calculated on μ-CT images was significantly larger in the FS-H group than in the MRONJ group (p = 0.021). Our findings suggest that a single local injection of fluvastatin following tooth extraction can potentially reduce the chance of developing MRONJ-like lesion in rats.
Identifiants
pubmed: 32221325
doi: 10.1038/s41598-020-61724-6
pii: 10.1038/s41598-020-61724-6
pmc: PMC7101417
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bone Density Conservation Agents
0
Diphosphonates
0
Denosumab
4EQZ6YO2HI
Fluvastatin
4L066368AS
Zoledronic Acid
6XC1PAD3KF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5620Références
Cremers, S., Drake, M. T., Ebetino, F. H., Bilezikian, J. P. & Russell, R. G. G. Pharmacology of bisphosphonates. Br. J. Clin. Pharmacol. 85, 1052–1062, https://doi.org/10.1111/bcp.13867 (2019).
doi: 10.1111/bcp.13867
pubmed: 30650219
pmcid: 30650219
Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [1]. J. Oral Maxillofac. Surg. 61, 1115–1117, https://doi.org/10.1016/S0278-2391(03)00720-1 (2003).
doi: 10.1016/S0278-2391(03)00720-1
pubmed: 12966493
pmcid: 12966493
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J. & Engroff, S. L. Osteonecrosis of the Jaws Associated with the Use of Bisphosphonates: A Review of 63 Cases. J. Oral Maxillofac. Surg. 62, 527–534, https://doi.org/10.1016/j.joms.2004.02.004 (2004).
doi: 10.1016/j.joms.2004.02.004
pubmed: 15122554
pmcid: 15122554
Migliorati, C. A., Schubert, M. M., Peterson, D. E. & Seneda, L. M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone - An emerging oral complication of supportive cancer therapy. Cancer 104, 83–93, https://doi.org/10.1002/cncr.21130 (2005).
doi: 10.1002/cncr.21130
pubmed: 15929121
pmcid: 15929121
Bagan, J. V. et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 42, 327–329, https://doi.org/10.1016/j.oraloncology.2005.08.001 (2006).
doi: 10.1016/j.oraloncology.2005.08.001
pubmed: 16275156
pmcid: 16275156
Aghaloo, T. L., Felsenfeld, A. L. & Tetradis, S. Osteonecrosis of the Jaw in a Patient on Denosumab. J. Oral Maxillofac. Surg. 68, 959–963, https://doi.org/10.1016/j.joms.2009.10.010 (2010).
doi: 10.1016/j.joms.2009.10.010
pubmed: 20149510
pmcid: 20149510
Taylor, K. H., Middlefell, L. S. & Mizen, K. D. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br. J. Oral Maxillofac. Surg. 48, 221–223, https://doi.org/10.1016/j.bjoms.2009.08.030 (2010).
doi: 10.1016/j.bjoms.2009.08.030
pubmed: 19836866
pmcid: 19836866
Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J. Oral Maxillofac. Surg. 72, 1938–1956, https://doi.org/10.1016/j.joms.2014.04.031 (2014).
doi: 10.1016/j.joms.2014.04.031
pubmed: 25234529
pmcid: 25234529
Khan, A. A. et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J. Clin. Densitom. 20, 8–24, https://doi.org/10.1016/j.jocd.2016.09.005 (2017).
doi: 10.1016/j.jocd.2016.09.005
pubmed: 27956123
pmcid: 27956123
Ristow, O. et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J. Craniomaxillofac. Surg. 47, 491–499, https://doi.org/10.1016/j.jcms.2018.12.014 (2019).
doi: 10.1016/j.jcms.2018.12.014
pubmed: 30642734
pmcid: 30642734
Melea, P. I. et al. Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. Int J Dent 2014, 427273, https://doi.org/10.1155/2014/427273 (2014).
doi: 10.1155/2014/427273
pubmed: 25045353
pmcid: 25045353
Bagan, J. et al. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Dis. 22, 324–329, https://doi.org/10.1111/odi.12447 (2016).
doi: 10.1111/odi.12447
pubmed: 26818808
pmcid: 26818808
Kakehashi, H. et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int. J. Oral Maxillofac. Surg. 44, 1558–1564, https://doi.org/10.1016/j.ijom.2015.07.018 (2015).
doi: 10.1016/j.ijom.2015.07.018
pubmed: 26304604
pmcid: 26304604
Jung, J. et al. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study. J. Bone Miner. Res. 32, 2445–2452, https://doi.org/10.1002/jbmr.3237 (2017).
doi: 10.1002/jbmr.3237
pubmed: 28815779
pmcid: 28815779
Heggendorn, F. L. et al. Bisphosphonate-related osteonecrosis of the jaws: Report of a case using conservative protocol. Spec. Care Dentist. 36, 43–47, https://doi.org/10.1111/scd.12143 (2016).
doi: 10.1111/scd.12143
pubmed: 26782365
pmcid: 26782365
Mauceri, R. et al. Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study. Biomed Res Int 2018, 3982540, https://doi.org/10.1155/2018/3982540 (2018).
doi: 10.1155/2018/3982540
pubmed: 30211221
pmcid: 30211221
Freiberger, J. J. et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: A randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J. Oral Maxillofac. Surg. 70, 1573–1583, https://doi.org/10.1016/j.joms.2012.04.001 (2012).
doi: 10.1016/j.joms.2012.04.001
pubmed: 22698292
pmcid: 22698292
Curi, M. M. et al. Bisphosphonate-Related Osteonecrosis of the Jaws-An Initial Case Series Report of Treatment Combining Partial Bone Resection and Autologous Platelet-Rich Plasma. J. Oral Maxillofac. Surg. 69, 2465–2472, https://doi.org/10.1016/j.joms.2011.02.078 (2011).
doi: 10.1016/j.joms.2011.02.078
pubmed: 21763050
pmcid: 21763050
Lesclous, P. et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone 45, 843–852, https://doi.org/10.1016/j.bone.2009.07.011 (2009).
doi: 10.1016/j.bone.2009.07.011
pubmed: 19631301
pmcid: 19631301
Zirk, M. et al. Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw. Clin. Oral Investig. 23, 2143–2151, https://doi.org/10.1007/s00784-018-2655-z (2019).
doi: 10.1007/s00784-018-2655-z
pubmed: 30276516
pmcid: 30276516
Allen, M. R. & Burr, D. B. Mandible Matrix Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate Treatment. J. Oral Maxillofac. Surg. 66, 987–994, https://doi.org/10.1016/j.joms.2008.01.038 (2008).
doi: 10.1016/j.joms.2008.01.038
pubmed: 18423290
pmcid: 18423290
Fournier, P. et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62, 6538–6544 (2002).
pubmed: 12438248
pmcid: 12438248
Santini, D. et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9, 2893–2897 (2003).
pubmed: 12912933
pmcid: 12912933
Gkouveris, I. et al. Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ). Bone 123, 234–245, https://doi.org/10.1016/j.bone.2019.03.031 (2019).
doi: 10.1016/j.bone.2019.03.031
pubmed: 30953717
pmcid: 30953717
Ravosa, M. J., Ning, J., Liu, Y. & Stack, M. S. Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch. Oral Biol. 56, 491–498, https://doi.org/10.1016/j.archoralbio.2010.11.003 (2011).
doi: 10.1016/j.archoralbio.2010.11.003
pubmed: 21146154
pmcid: 21146154
Soydan, S. S. et al. Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts. Hum. Exp. Toxicol. 34, 1073–1082, https://doi.org/10.1177/0960327115569808 (2015).
doi: 10.1177/0960327115569808
pubmed: 25636638
pmcid: 25636638
Zhang, Q. et al. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin. Cancer Res. 19, 3176–3188, https://doi.org/10.1158/1078-0432.Ccr-13-0042 (2013).
doi: 10.1158/1078-0432.Ccr-13-0042
pubmed: 23616636
pmcid: 23616636
Zhu, W. et al. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J. 33, 5208–5219, https://doi.org/10.1096/fj.201801791RR (2019).
doi: 10.1096/fj.201801791RR
pubmed: 30624969
pmcid: 30624969
Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946–1949, https://doi.org/10.1126/science.286.5446.1946 (1999).
doi: 10.1126/science.286.5446.1946
pubmed: 10583956
pmcid: 10583956
Ayukawa, Y., Okamura, A. & Koyano, K. Simvastatin promotes osteogenesis around titanium implants. Clin. Oral Implants Res. 15, 346–350, https://doi.org/10.1046/j.1600-0501.2003.01015.x (2004).
doi: 10.1046/j.1600-0501.2003.01015.x
pubmed: 15142098
pmcid: 15142098
Sakoda, K. et al. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J. Dent. Res. 85, 520–523, https://doi.org/10.1177/154405910608500608 (2006).
doi: 10.1177/154405910608500608
pubmed: 16723648
pmcid: 16723648
Hassan, H. M., Al-Gayyar, M. M. H., El-Gayar, A. M. & Ibrahim, T. M. Effect of simvastatin on inflammatory cytokines balance in air pouch granuloma model. Inflammation and Allergy - Drug Targets 13, 74–79, https://doi.org/10.2174/1871528112666131230012026 (2014).
doi: 10.2174/1871528112666131230012026
pubmed: 24372369
pmcid: 24372369
Jerwood, S. & Cohen, J. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother. 61, 362–364, https://doi.org/10.1093/jac/dkm496 (2008).
doi: 10.1093/jac/dkm496
pubmed: 18086693
pmcid: 18086693
Ko, H. H. T., Lareu, R. R., Dix, B. R. & Hughes, J. D. In vitro antibacterial effects of statins against bacterial pathogens causing skin infections. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1125–1135, https://doi.org/10.1007/s10096-018-3227-5 (2018).
doi: 10.1007/s10096-018-3227-5
pubmed: 29569046
pmcid: 29569046
Altieri, D. C. Statins’ benefits begin to sprout. J. Clin. Invest. 108, 365–366, https://doi.org/10.1172/jci13556 (2001).
doi: 10.1172/jci13556
pubmed: 11489928
pmcid: 11489928
Zhang, Y. et al. Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia. Mol. Biol. Rep. 39, 285–293, https://doi.org/10.1007/s11033-011-0737-y (2012).
doi: 10.1007/s11033-011-0737-y
pubmed: 21553056
pmcid: 21553056
Yasunami, N. et al. Acceleration of hard and soft tissue healing in the oral cavity by a single transmucosal injection of fluvastatin-impregnated poly (lactic-co-glycolic acid) microspheres. An in vitro and rodent in vivo study. Biomed. Mater. 11, 015001, https://doi.org/10.1088/1748-6041/11/1/015001 (2015).
doi: 10.1088/1748-6041/11/1/015001
The ARRIVE Guidelines: Animal Research: Reporting of In Vivo Experiments, https://www.nc3rs.org.uk/sites/default/files/documents/Guidelines/NC3Rs%20ARRIVE%20Guidelines%202013.pdf .
Kaibuchi, N., Iwata, T., Yamato, M., Okano, T. & Ando, T. Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model. Acta Biomater. 42, 400–410, https://doi.org/10.1016/j.actbio.2016.06.022 (2016).
doi: 10.1016/j.actbio.2016.06.022
pubmed: 27326918
pmcid: 27326918
Kuroshima, S., Entezami, P., McCauley, L. K. & Yamashita, J. Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing. Osteoporos. Int. 25, 1141–1150, https://doi.org/10.1007/s00198-013-2570-8 (2014).
doi: 10.1007/s00198-013-2570-8
pubmed: 24301537
pmcid: 24301537
Araújo, M. G., Wennström, J. L. & Lindhe, J. Modeling of the buccal and lingual bone walls of fresh extraction sites following implant installation. Clin. Oral Implants Res. 17, 606–614, https://doi.org/10.1111/j.1600-0501.2006.01315.x (2006).
doi: 10.1111/j.1600-0501.2006.01315.x
pubmed: 17092217
pmcid: 17092217
Ogata, K. et al. Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model. Bone 74, 95–105, https://doi.org/10.1016/j.bone.2015.01.011 (2015).
doi: 10.1016/j.bone.2015.01.011
pubmed: 25613174
pmcid: 25613174
Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341–1347, https://doi.org/10.1093/annonc/mdr435 (2012).
doi: 10.1093/annonc/mdr435
pubmed: 21986094
pmcid: 21986094
Aghaloo, T. L. et al. RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J. Bone Miner. Res. 29, 843–854, https://doi.org/10.1002/jbmr.2097 (2014).
doi: 10.1002/jbmr.2097
pubmed: 24115073
pmcid: 24115073
Vukelic, S. et al. Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor. J. Biol. Chem. 285, 1980–1988, https://doi.org/10.1074/jbc.M109.016741 (2010).
doi: 10.1074/jbc.M109.016741
pubmed: 19903814
pmcid: 19903814
Kureishi, Y. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004–1010, https://doi.org/10.1038/79510 (2000).
doi: 10.1038/79510
pubmed: 10973320
pmcid: 10973320
Greenwood, J., Steinman, L. & Zamvil, S. S. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nature Reviews Immunology 6, 358–370, https://doi.org/10.1038/nri1839 (2006).
doi: 10.1038/nri1839
pubmed: 16639429
pmcid: 16639429
Thangamani, S. et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci. Rep. 5, 16407, https://doi.org/10.1038/srep16407 (2015).
doi: 10.1038/srep16407
pubmed: 26553420
pmcid: 26553420
Gupta, M. & Kumar, A. Comparison of Minimum Inhibitory Concentration (MIC) value of statin drugs: A Systematic Review. Anti-Infective Agents 17, 4–19, https://doi.org/10.2174/2211352516666180629124433 (2018).
doi: 10.2174/2211352516666180629124433
Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nature Reviews Drug Discovery 4, 977–987, https://doi.org/10.1038/nrd1901 (2005).
doi: 10.1038/nrd1901
pubmed: 16341063
pmcid: 16341063
Li, X., Cui, Q., Kao, C., Wang, G. J. & Balian, G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33, 652–659, https://doi.org/10.1016/s8756-3282(03)00239-4 (2003).
doi: 10.1016/s8756-3282(03)00239-4
pubmed: 14555271
pmcid: 14555271
Ohnaka, K. et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287, 337–342, https://doi.org/10.1006/bbrc.2001.5597 (2001).
doi: 10.1006/bbrc.2001.5597
pubmed: 11554731
pmcid: 11554731
Oryan, A., Kamali, A. & Moshiri, A. Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions. J. Control. Release 215, 12–24, https://doi.org/10.1016/j.jconrel.2015.07.022 (2015).
doi: 10.1016/j.jconrel.2015.07.022
pubmed: 26226345
pmcid: 26226345
Galus, R., Wlodarski, P. K. & Wlodarski, K. H. Fluvastatin increases heterotopically induced ossicles in mice. Clin. Exp. Pharmacol. Physiol. 33, 388–390, https://doi.org/10.1111/j.1440-1681.2006.04380.x (2006).
doi: 10.1111/j.1440-1681.2006.04380.x
pubmed: 16620306
pmcid: 16620306
Galus, R., Wlodarski, P. & Wlodarski, K. Influence of fluvastatin on bone formation induced by demineralized bone matrix in mice. Pharmacol. Rep. 58, 443–447 (2006).
pubmed: 16845222
pmcid: 16845222
Kuroshima, S. & Yamashita, J. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice. Bone 56, 101–109, https://doi.org/10.1016/j.bone.2013.05.013 (2013).
doi: 10.1016/j.bone.2013.05.013
pubmed: 23727433
pmcid: 23727433
García, M. J., Reinoso, R. F., Sánchez Navarro, A. & Prous, J. R. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 25, 457–481 (2003).
doi: 10.1358/mf.2003.25.6.769652
pubmed: 12949632
pmcid: 12949632
Ayukawa, Y. et al. Simvastatin enhances bone formation around titanium implants in rat tibiae. J. Oral Rehabil. 37, 123–130, https://doi.org/10.1111/j.1365-2842.2009.02011.x (2010).
doi: 10.1111/j.1365-2842.2009.02011.x
pubmed: 19889034
pmcid: 19889034